Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer.

Lohrmann C, O'Reilly EM, O'Donoghue JA, Pandit-Taskar N, Carrasquillo JA, Lyashchenko SK, Ruan S, Teng R, Scholz W, Maffuid PW, Lewis JS, Weber WA.

Clin Cancer Res. 2019 Dec 1;25(23):7014-7023. doi: 10.1158/1078-0432.CCR-18-3667. Epub 2019 Sep 20.

PMID:
31540979
2.

Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan.

Reidy-Lagunes D, Pandit-Taskar N, O'Donoghue JA, Krebs S, Staton KD, Lyashchenko SK, Lewis JS, Raj N, Gönen M, Lohrmann C, Bodei L, Weber WA.

Clin Cancer Res. 2019 Dec 1;25(23):6939-6947. doi: 10.1158/1078-0432.CCR-19-1026. Epub 2019 Aug 22.

PMID:
31439583
3.

89Zr-Immuno-PET: Toward a Noninvasive Clinical Tool to Measure Target Engagement of Therapeutic Antibodies In Vivo.

Jauw YWS, O'Donoghue JA, Zijlstra JM, Hoekstra OS, Menke-van der Houven van Oordt CW, Morschhauser F, Carrasquillo JA, Zweegman S, Pandit-Taskar N, Lammertsma AA, van Dongen GAMS, Boellaard R, Weber WA, Huisman MC.

J Nucl Med. 2019 Dec;60(12):1825-1832. doi: 10.2967/jnumed.118.224568. Epub 2019 May 30.

PMID:
31147401
4.

Pharmacokinetics and Biodistribution of a [89Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients.

O'Donoghue JA, Danila DC, Pandit-Taskar N, Beylergil V, Cheal SM, Fleming SE, Fox JJ, Ruan S, Zanzonico PB, Ragupathi G, Lyashchenko SK, Williams SP, Scher HI, Fine BM, Humm JL, Larson SM, Morris MJ, Carrasquillo JA.

Mol Pharm. 2019 Jul 1;16(7):3083-3090. doi: 10.1021/acs.molpharmaceut.9b00326. Epub 2019 May 31.

PMID:
31117485
5.

Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using 89Zr-DFO-MSTP2109A Anti-STEAP1 Antibody.

Carrasquillo JA, Fine BM, Pandit-Taskar N, Larson SM, Fleming SE, Fox JJ, Cheal SM, O'Donoghue JA, Ruan S, Ragupathi G, Lyashchenko SK, Humm JL, Scher HI, Gönen M, Williams SP, Danila DC, Morris MJ.

J Nucl Med. 2019 Nov;60(11):1517-1523. doi: 10.2967/jnumed.118.222844. Epub 2019 May 3.

PMID:
31053681
6.

Biodistribution and radiation dose estimates for 68Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors.

Krebs S, Pandit-Taskar N, Reidy D, Beattie BJ, Lyashchenko SK, Lewis JS, Bodei L, Weber WA, O'Donoghue JA.

Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):677-685. doi: 10.1007/s00259-018-4193-y. Epub 2018 Oct 29.

PMID:
30374529
7.

I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma.

Carrasquillo JA, O'Donoghue JA, Beylergil V, Ruan S, Pandit-Taskar N, Larson SM, Smith-Jones PM, Lyashchenko SK, Ohishi N, Ohtomo T, Abou-Alfa GK.

EJNMMI Res. 2018 Mar 5;8(1):20. doi: 10.1186/s13550-018-0374-8.

8.

First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using 89Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer.

Ulaner GA, Lyashchenko SK, Riedl C, Ruan S, Zanzonico PB, Lake D, Jhaveri K, Zeglis B, Lewis JS, O'Donoghue JA.

J Nucl Med. 2018 Jun;59(6):900-906. doi: 10.2967/jnumed.117.202010. Epub 2017 Nov 16.

9.

Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89Zr-Trastuzumab in Patients with Esophagogastric Cancer.

O'Donoghue JA, Lewis JS, Pandit-Taskar N, Fleming SE, Schöder H, Larson SM, Beylergil V, Ruan S, Lyashchenko SK, Zanzonico PB, Weber WA, Carrasquillo JA, Janjigian YY.

J Nucl Med. 2018 Jan;59(1):161-166. doi: 10.2967/jnumed.117.194555. Epub 2017 Jun 21.

10.

Monitoring early response to chemoradiotherapy with 18F-FMISO dynamic PET in head and neck cancer.

Grkovski M, Lee NY, Schöder H, Carlin SD, Beattie BJ, Riaz N, Leeman JE, O'Donoghue JA, Humm JL.

Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1682-1691. doi: 10.1007/s00259-017-3720-6. Epub 2017 May 24.

11.

Multiparametric Imaging of Tumor Hypoxia and Perfusion with 18F-Fluoromisonidazole Dynamic PET in Head and Neck Cancer.

Grkovski M, Schöder H, Lee NY, Carlin SD, Beattie BJ, Riaz N, Leeman JE, O'Donoghue JA, Humm JL.

J Nucl Med. 2017 Jul;58(7):1072-1080. doi: 10.2967/jnumed.116.188649. Epub 2017 Feb 9.

12.

Bombesin Antagonist-Based Radiotherapy of Prostate Cancer Combined with WST-11 Vascular Targeted Photodynamic Therapy.

Kim K, Zhang H, La Rosa S, Jebiwott S, Desai P, Kimm S, Scherz A, O'Donoghue JA, Weber WA, Coleman JA.

Clin Cancer Res. 2017 Jul 1;23(13):3343-3351. doi: 10.1158/1078-0432.CCR-16-2745. Epub 2017 Jan 20.

13.

First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.

Pandit-Taskar N, O'Donoghue JA, Ruan S, Lyashchenko SK, Carrasquillo JA, Heller G, Martinez DF, Cheal SM, Lewis JS, Fleisher M, Keppler JS, Reiter RE, Wu AM, Weber WA, Scher HI, Larson SM, Morris MJ.

J Nucl Med. 2016 Dec;57(12):1858-1864. Epub 2016 Aug 11.

14.

Copper-64 trastuzumab PET imaging: a reproducibility study.

Carrasquillo JA, Morris PG, Humm JL, Smith-Jones PM, Beylergil V, Akhurst T, O'donoghue JA, Ruan S, Modi S, Hudis CA, Larson SM.

Q J Nucl Med Mol Imaging. 2019 Jun;63(2):191-198. doi: 10.23736/S1824-4785.16.02867-3. Epub 2016 May 12.

PMID:
27171605
15.

PET-based compartmental modeling of (124)I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer.

Zanzonico P, Carrasquillo JA, Pandit-Taskar N, O'Donoghue JA, Humm JL, Smith-Jones P, Ruan S, Divgi C, Scott AM, Kemeny NE, Fong Y, Wong D, Scheinberg D, Ritter G, Jungbluth A, Old LJ, Larson SM.

Eur J Nucl Med Mol Imaging. 2015 Oct;42(11):1700-1706. doi: 10.1007/s00259-015-3061-2. Epub 2015 Jul 21.

16.

A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.

Pandit-Taskar N, O'Donoghue JA, Durack JC, Lyashchenko SK, Cheal SM, Beylergil V, Lefkowitz RA, Carrasquillo JA, Martinez DF, Fung AM, Solomon SB, Gönen M, Heller G, Loda M, Nanus DM, Tagawa ST, Feldman JL, Osborne JR, Lewis JS, Reuter VE, Weber WA, Bander NH, Scher HI, Larson SM, Morris MJ.

Clin Cancer Res. 2015 Dec 1;21(23):5277-85. doi: 10.1158/1078-0432.CCR-15-0552. Epub 2015 Jul 14.

17.

Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors.

Pandit-Taskar N, O'Donoghue JA, Divgi CR, Wills EA, Schwartz L, Gönen M, Smith-Jones P, Bander NH, Scher HI, Larson SM, Morris MJ.

EJNMMI Res. 2015 Apr 29;5:28. doi: 10.1186/s13550-015-0104-4. eCollection 2015.

18.

⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.

Pandit-Taskar N, O'Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, Durack JC, Carrasquillo JA, Lefkowitz RA, Gonen M, Lewis JS, Holland JP, Cheal SM, Reuter VE, Osborne JR, Loda MF, Smith-Jones PM, Weber WA, Bander NH, Scher HI, Morris MJ, Larson SM.

Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2093-105. doi: 10.1007/s00259-014-2830-7. Epub 2014 Aug 21.

19.

Pilot study of PET imaging of 124I-iodoazomycin galactopyranoside (IAZGP), a putative hypoxia imaging agent, in patients with colorectal cancer and head and neck cancer.

O'Donoghue JA, Guillem JG, Schöder H, Lee NY, Divgi CR, Ruby JA, Humm JL, Lee-Kong SA, Burnazi EM, Cai S, Carlin SD, Leibold T, Zanzonico PB, Ling CC.

EJNMMI Res. 2013 Jun 3;3(1):42. doi: 10.1186/2191-219X-3-42.

20.

Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer.

Carrasquillo JA, O'Donoghue JA, Pandit-Taskar N, Humm JL, Rathkopf DE, Slovin SF, Williamson MJ, Lacuna K, Aksnes AK, Larson SM, Scher HI, Morris MJ.

Eur J Nucl Med Mol Imaging. 2013 Sep;40(9):1384-93. doi: 10.1007/s00259-013-2427-6. Epub 2013 May 8.

21.

Bone marrow dosimetry using 124I-PET.

Schwartz J, Humm JL, Divgi CR, Larson SM, O'Donoghue JA.

J Nucl Med. 2012 Apr;53(4):615-21. doi: 10.2967/jnumed.111.096453. Epub 2012 Mar 13.

22.

Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging.

Stillebroer AB, Zegers CM, Boerman OC, Oosterwijk E, Mulders PF, O'Donoghue JA, Visser EP, Oyen WJ.

J Nucl Med. 2012 Jan;53(1):82-9. doi: 10.2967/jnumed.111.094896. Epub 2011 Dec 12.

23.

124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET.

O'Donoghue JA, Smith-Jones PM, Humm JL, Ruan S, Pryma DA, Jungbluth AA, Divgi CR, Carrasquillo JA, Pandit-Taskar N, Fong Y, Strong VE, Kemeny NE, Old LJ, Larson SM.

J Nucl Med. 2011 Dec;52(12):1878-85. doi: 10.2967/jnumed.111.095596. Epub 2011 Nov 8.

24.

(124)I-huA33 antibody PET of colorectal cancer.

Carrasquillo JA, Pandit-Taskar N, O'Donoghue JA, Humm JL, Zanzonico P, Smith-Jones PM, Divgi CR, Pryma DA, Ruan S, Kemeny NE, Fong Y, Wong D, Jaggi JS, Scheinberg DA, Gonen M, Panageas KS, Ritter G, Jungbluth AA, Old LJ, Larson SM.

J Nucl Med. 2011 Aug;52(8):1173-80. doi: 10.2967/jnumed.110.086165. Epub 2011 Jul 15.

25.

Correlation of in vivo and in vitro measures of carbonic anhydrase IX antigen expression in renal masses using antibody 124I-cG250.

Pryma DA, O'Donoghue JA, Humm JL, Jungbluth AA, Old LJ, Larson SM, Divgi CR.

J Nucl Med. 2011 Apr;52(4):535-40. doi: 10.2967/jnumed.110.083295. Epub 2011 Mar 18.

26.

18F-fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors.

Oehler C, O'Donoghue JA, Russell J, Zanzonico P, Lorenzen S, Ling CC, Carlin S.

J Nucl Med. 2011 Mar;52(3):437-44. doi: 10.2967/jnumed.110.081372. Epub 2011 Feb 14.

27.

Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody.

Schwartz J, Jaggi JS, O'Donoghue JA, Ruan S, McDevitt M, Larson SM, Scheinberg DA, Humm JL.

Phys Med Biol. 2011 Feb 7;56(3):721-33. doi: 10.1088/0031-9155/56/3/012. Epub 2011 Jan 10.

28.

High 18F-FDG uptake in microscopic peritoneal tumors requires physiologic hypoxia.

Li XF, Ma Y, Sun X, Humm JL, Ling CC, O'Donoghue JA.

J Nucl Med. 2010 Apr;51(4):632-8. doi: 10.2967/jnumed.109.071233.

29.

Detection of hypoxia in microscopic tumors using 131I-labeled iodo-azomycin galactopyranoside (131I-IAZGP) digital autoradiography.

Li XF, Sun X, Ma Y, Suehiro M, Zhang M, Russell J, Humm JL, Ling CC, O'Donoghue JA.

Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):339-48. doi: 10.1007/s00259-009-1310-y. Epub 2009 Nov 17.

30.

Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy.

Pandit-Taskar N, O'Donoghue JA, Morris MJ, Wills EA, Schwartz LH, Gonen M, Scher HI, Larson SM, Divgi CR.

J Nucl Med. 2008 Jul;49(7):1066-74. doi: 10.2967/jnumed.107.049502. Epub 2008 Jun 13.

31.

Hypoxia in microscopic tumors.

Li XF, O'Donoghue JA.

Cancer Lett. 2008 Jun 18;264(2):172-80. doi: 10.1016/j.canlet.2008.02.037. Epub 2008 Apr 1. Review.

32.

Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy.

Li XF, Carlin S, Urano M, Russell J, Ling CC, O'Donoghue JA.

Cancer Res. 2007 Aug 15;67(16):7646-53.

33.

Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors.

Morris MJ, Pandit-Taskar N, Divgi CR, Bender S, O'Donoghue JA, Nacca A, Smith-Jones P, Schwartz L, Slovin S, Finn R, Larson S, Scher HI.

Clin Cancer Res. 2007 May 1;13(9):2707-13.

34.

Measurements of partial oxygen pressure pO2 using the OxyLite system in R3327-AT tumors under isoflurane anesthesia.

Wen B, Urano M, O'Donoghue JA, Ling CC.

Radiat Res. 2006 Sep;166(3):512-8.

PMID:
16953670
35.

Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer.

Morris MJ, Divgi CR, Pandit-Taskar N, Batraki M, Warren N, Nacca A, Smith-Jones P, Schwartz L, Kelly WK, Slovin S, Solit D, Halpern J, Delacruz A, Curley T, Finn R, O'donoghue JA, Livingston P, Larson S, Scher HI.

Clin Cancer Res. 2005 Oct 15;11(20):7454-61.

36.

Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM.

Burgman P, O'Donoghue JA, Lewis JS, Welch MJ, Humm JL, Ling CC.

Nucl Med Biol. 2005 Aug;32(6):623-30.

PMID:
16026709
37.

Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.

O'Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, Burnazi E, Finn RD, Burgman P, Ruan S, Lewis JS, Welch MJ, Ling CC, Humm JL.

Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1493-502.

PMID:
15817355
38.

Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer.

Divgi CR, O'Donoghue JA, Welt S, O'Neel J, Finn R, Motzer RJ, Jungbluth A, Hoffman E, Ritter G, Larson SM, Old LJ.

J Nucl Med. 2004 Aug;45(8):1412-21.

39.

A stereotactic method for the three-dimensional registration of multi-modality biologic images in animals: NMR, PET, histology, and autoradiography.

Humm JL, Ballon D, Hu YC, Ruan S, Chui C, Tulipano PK, Erdi A, Koutcher J, Zakian K, Urano M, Zanzonico P, Mattis C, Dyke J, Chen Y, Harrington P, O'Donoghue JA, Ling CC.

Med Phys. 2003 Sep;30(9):2303-14.

PMID:
14528951
40.

Changes in FDG Tumor Uptake during and after Fractionated Radiation Therapy in a Rodent Tumor Xenograft.

Humm JL, Lee J, O'Donoghue JA, Squire O, Ling CC, Pentlow K, Mehta B, Erdi Y, Ruan S, Larson SM.

Clin Positron Imaging. 1999 Oct;2(5):289-296.

PMID:
14516653
41.

Hematologic toxicity in radioimmunotherapy: dose-response relationships for I-131 labeled antibody therapy.

O'Donoghue JA, Baidoo N, Deland D, Welt S, Divgi CR, Sgouros G.

Cancer Biother Radiopharm. 2002 Aug;17(4):435-43.

PMID:
12396707
42.

Iodination of annexin V for imaging apoptosis.

Russell J, O'Donoghue JA, Finn R, Koziorowski J, Ruan S, Humm JL, Ling CC.

J Nucl Med. 2002 May;43(5):671-7.

43.

Rationales, evidence, and design considerations for fractionated radioimmunotherapy.

DeNardo GL, Schlom J, Buchsbaum DJ, Meredith RF, O'Donoghue JA, Sgouros G, Humm JL, DeNardo SJ.

Cancer. 2002 Feb 15;94(4 Suppl):1332-48.

44.

Relative therapeutic efficacy of (125)I- and (131)I-labeled monoclonal antibody A33 in a human colon cancer xenograft.

Barendswaard EC, Humm JL, O'Donoghue JA, Sgouros G, Finn RD, Scott AM, Larson SM, Welt S.

J Nucl Med. 2001 Aug;42(8):1251-6.

45.

Optimizing the sequence of combination therapy with radiolabeled antibodies and fractionated external beam.

Ruan S, O'Donoghue JA, Larson SM, Finn RD, Jungbluth A, Welt S, Humm JL.

J Nucl Med. 2000 Nov;41(11):1905-12.

46.

Tumor Burden Assessment with Positron Emission Tomography with

Akhurst T, Ng V V, Larson SM, O'Donoghue JA, O'Neel J, Erdi Y, Divgi CR.

Clin Positron Imaging. 2000 Mar;3(2):57-65.

PMID:
10838401
47.

Single-dose versus fractionated radioimmunotherapy: model comparisons for uniform tumor dosimetry.

O'Donoghue JA, Sgouros G, Divgi CR, Humm JL.

J Nucl Med. 2000 Mar;41(3):538-47.

48.

131I radioimmunotherapy and fractionated external beam radiotherapy: comparative effectiveness in a human tumor xenograft.

Barendswaard EC, O'Donoghue JA, Larson SM, Tschmelitsch J, Welt S, Finn RD, Humm JL.

J Nucl Med. 1999 Oct;40(10):1764-8.

49.

Implications of nonuniform tumor doses for radioimmunotherapy.

O'Donoghue JA.

J Nucl Med. 1999 Aug;40(8):1337-41.

50.

Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma.

Divgi CR, Bander NH, Scott AM, O'Donoghue JA, Sgouros G, Welt S, Finn RD, Morrissey F, Capitelli P, Williams JM, Deland D, Nakhre A, Oosterwijk E, Gulec S, Graham MC, Larson SM, Old LJ.

Clin Cancer Res. 1998 Nov;4(11):2729-39.

Supplemental Content

Loading ...
Support Center